Role SummaryAstraZeneca is accelerating the expansion of our geographical footprint in rare diseases following the acquisition of Alexion in 2021. Rare disease is a high-growth therapy area with rapid innovation and significant unmet medical need. Over 7,000 rare diseases are known today – yet less than 1% of them have an approved treatment.